References
- Rodnan GP, ed. Primer on the rheumatic diseases. 7th ed. Atlanta: Arthritis Foundation, 1973
- Schumacher HR, Zvaifler NJ, Rodnan GP. Primer on the rheumatic diseases. 8th ed. Atlanta: Arthritis Foundation, 1983
- Wolfe F. 50 years of antirheumatic therapy: the prognosis of rheumatoid arthritis. J Rheumatol Suppl 1990: 22: 24–32
- Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the “sawtooth” strategy. J Rheumatol Suppl 1990: 22: 12–5
- Klippel JH, Strober S, Wofsy D. New therapies for the rheumatic diseases. Bull Rheum Dis 1989: 38(4): 1–8
- Wilder RL. Treatment of the patient with rheumatoid arthritis refractory to standard therapy. JAMA 1988: 259(16): 2446–9
- Yunus MB. Investigational therapy in rheumatoid arthritis: a critical review. Semin Arthritis Rheum 1988: 17(3): 163–84
- Grindulis KA, McConkey B. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone. Ann Rheum Dis 1984: 43(3): 398–401
- Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984: 27(8): 864–72
- Makisara GL, Makisara P. Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol 1982: 1(2): 117–25
- Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987: 30(5): 507–12
- Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987: 1(8542): 1108–11
- Schumacher HR. Primer on the rheumatic diseases. 9th ed. Atlanta: Arthritis Foundation, 1988
- Butt JH, Barthel JS, Moore RA. Clinical spectrum of the upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: natural history, symptomatology, and significance. Am J Med 1988: 84(2A): 5–14
- Lockie LM, Smith DM. Forty-seven years experience with gold therapy in 1,019 rheumatoid arthritis patients. Semin Arthritis Rheum 1985: 14(4): 238–46
- Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980: 303(18): 1038–41
- Fletcher RH. The clinical importance of placebo effects. Fam Med Rev 1983: 1: 40–8
- Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chronic Dis 1985: 38(12): 973–84
- Smith T. Poverty and health in the 1990s. (Editorial) BMJ 1990: 301(6748): 349–50
- Ziff M. Rheumatoid arthritis: its present and future. J Rheumatoid 1990: 17(2): 127–33
- Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990: 335(8697): 1051–5
- Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 1989: 16(2): 158–63
- Randall T. Thalidomide's back in the news, but in more favorable circumstances. JAMA 1990: 263(11): 1467–8
- Corman LC, Bell CL, Edwards NL, et al. Rheumatology for the house officer. Baltimore: Williams & Wilkins, 1990
Selected Readings
- Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988: 31(3): 315–24
- Drugs for rheumatoid arthritis. Med Lett Drugs Ther 1987: 29(734): 21–4
- Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990: 322(18): 1277–89 [erratum, N Engl J Med 1990: 323(14): 996]
- Kazis LE, Anderson JJ, Meenan RE Health status as a predictor of morality in rheumatoid arthritis: a five-year study. J Rheumatol 1990: 17(5): 609–13
- Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987: 16(3): 206–21
- Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986: 29(6): 706–14
- Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990: 33(1): 9–18
- O'Sullivan JB, Cathcart ES. The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972: 76(4): 573–7
- Paulus HE. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990: 33(1): 113–20
- Pinals RS. Sulfasalazine in rheumatic disease. Semin Arthritis Rheum 1988: 17(4): 246–59
- Sherrer YS, Bloch DA, Mitchell DM, et al. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986: 29(4): 494–500